Vator Securities: Unlocking US reimbursement – the share price catalyst during 2021
SciBase is delivering as we expected, and the share price is closing in on our target price. Recent news flow confirms the Nevisense EIS-technology’s potential for skin barrier assessment applications – an upside to both our and the market’s valuation of the company. The apparent tangible driver of the share price for the coming 12 months, however, is unlocking US reimbursement (Medicare) where the US company DermTech offers a clear blueprint. DermTech (DMTK: Nasdaq US) is a close peer to SciBase, commercializing a molecular assay for melanoma detection in the US. DermTech generated